ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer

Nat Cancer. 2021 May;2(5):503-514. doi: 10.1038/s43018-021-00208-6.

Jiehui Deng ¹, Aatish Thennavan ², Igor Dolgalev ³, Ting Chen ¹, Jie Li ³ ⁴, Antonio Marzio ³ ⁴, John T Poirier ⁵, David H Peng ¹, Mirna Bulatovic ¹, Subhadip Mukhopadhyay ⁶, Heather Silver ¹, Eleni Papadopoulos ¹, Val Pyon ¹, Cassandra Thakurdin ¹, Han Han ¹, Fei Li ¹, Shuai Li ¹, Hailin Ding ¹, Hai Hu ¹, Yuanwang Pan ¹, Vajira Weerasekara ⁷ ⁸, Baishan Jiang ⁹ ¹⁰, Eric S Wang ⁹ ¹⁰, Ian Ahearn ¹¹, Mark Philips ¹¹, Thales Papagiannakopoulos ³ ¹², Aristotelis Tsirigos ³, Eli Rothenberg ⁴, Justin Gainor ⁷, Gordon J Freeman ¹³, Charles M Rudin ¹⁴, Nathanael S Gray ¹⁵, Peter S Hammerman ¹³, Michele Pagano ³ ⁴ ¹⁶, John V Heymach ¹⁷, Charles M Perou ², Nabeel Bardeesy ⁷ ⁸, Kwok-Kin Wong ¹⁸

Affiliations

1 Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
2 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
3 Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, NY, USA.
4 Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
5 Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
7 Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
8 Department of Medicine, Harvard Medical School, Boston, MA, USA.
9 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
10 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
11 Department of Medicine, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.
12 Department of Pathology, New York University School of Medicine, New York, NY, USA.
13 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
14 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
15 Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
16 Howard Hughes Medical Institute, New York University School of Medicine, New York, NY, USA.
17 Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
18 Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA. [email protected].

PMID: 34142094 DOI: 10.1038/s43018-021-00208-6

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-100006A

MRT68921 dihydrochloride

99.67%, ULK1/2 Inhibitor

ULK

Cancer

Name
Email *

	Sorry, but the email address you supplied was invalid.